Trial Profile
Evaluation of Clinical Efficacy and Immunogenicity of Drug Eritromax® at Blau Farmacêutica S.A. Compared to Eprex®, Produced by Janssen-Cilag Laboratory in Participants With Secondary Anemia to Chronic Kidney Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- 17 Aug 2018 Status changed from recruiting to discontinued.
- 06 Apr 2016 Planned End Date changed from 1 Feb 2016 to 1 Apr 2017, according to ClinicalTrials.gov record.
- 06 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.